Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Kasus-Jacobi

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Clinical Pharmacology|January 20, 2009
State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseasesMark A Babizhayev, Anne Kasus-Jacobi
Journal of Drug Targeting|November 28, 2008
N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complicationsMark A Babizhayev, Andrea Guiotto, Anne Kasus-Jacobi
Advances in Wound Care|June 16, 2017
Bioactive Antimicrobial Peptides as Therapeutics for Corneal Wounds and InfectionsGina L Griffith, Anne Kasus-Jacobi, H Anne Pereira
Journal of Neuroinflammation|August 29, 2018
The role of neutrophil granule proteins in neuroinflammation and Alzheimer's diseaseAmanda J Stock, Anne Kasus-Jacobi, H Anne Pereira
American Journal of Therapeutics|June 3, 2009
N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patientsMark A Babizhayev, Philip Micans, Andrea Guiotto, et al.
Fundamental & Clinical Pharmacology|July 29, 2011
Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision careMark A Babizhayev, Inna P Khoroshilova-Maslova, Anne Kasus-Jacobi
Journal of Ocular Diseases and Therapeutics|December 14, 2018
Effect of Cationic Antimicrobial Protein CAP37 on Cytokine Profile during Corneal Wound HealingAnne Kasus-Jacobi, Gina L Griffith, Megan Lerner, et al.
Investigative Ophthalmology & Visual Science|July 17, 2014
Corneal wound healing, a newly identified function of CAP37, is mediated by protein kinase C delta (PKCδ)Gina L Griffith, Anne Kasus-Jacobi, Megan R Lerner, et al.
Current Alzheimer Research|August 25, 2021
Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and NeurotoxicityAnne Kasus-Jacobi, Jennifer L Washburn, Craig A Land, et al.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|June 10, 2014
Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provisionMark A Babizhayev, Anne Kasus-Jacobi, Khava S Vishnyakova, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Clinical Pharmacology|January 20, 2009
State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseasesMark A Babizhayev, Anne Kasus-Jacobi
Journal of Drug Targeting|November 28, 2008
N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complicationsMark A Babizhayev, Andrea Guiotto, Anne Kasus-Jacobi
Advances in Wound Care|June 16, 2017
Bioactive Antimicrobial Peptides as Therapeutics for Corneal Wounds and InfectionsGina L Griffith, Anne Kasus-Jacobi, H Anne Pereira
Journal of Neuroinflammation|August 29, 2018
The role of neutrophil granule proteins in neuroinflammation and Alzheimer's diseaseAmanda J Stock, Anne Kasus-Jacobi, H Anne Pereira
American Journal of Therapeutics|June 3, 2009
N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patientsMark A Babizhayev, Philip Micans, Andrea Guiotto, et al.
Fundamental & Clinical Pharmacology|July 29, 2011
Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision careMark A Babizhayev, Inna P Khoroshilova-Maslova, Anne Kasus-Jacobi
Journal of Ocular Diseases and Therapeutics|December 14, 2018
Effect of Cationic Antimicrobial Protein CAP37 on Cytokine Profile during Corneal Wound HealingAnne Kasus-Jacobi, Gina L Griffith, Megan Lerner, et al.
Investigative Ophthalmology & Visual Science|July 17, 2014
Corneal wound healing, a newly identified function of CAP37, is mediated by protein kinase C delta (PKCδ)Gina L Griffith, Anne Kasus-Jacobi, Megan R Lerner, et al.
Current Alzheimer Research|August 25, 2021
Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and NeurotoxicityAnne Kasus-Jacobi, Jennifer L Washburn, Craig A Land, et al.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|June 10, 2014
Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provisionMark A Babizhayev, Anne Kasus-Jacobi, Khava S Vishnyakova, et al.
Pageof 3